Your browser doesn't support javascript.
loading
Appendiceal Neuroendocrine Neoplasms: an Update for 2023.
Holmager, Pernille; Langer, Seppo W; Kjaer, Andreas; Ringholm, Lene; Garbyal, Rajendra Singh; Hansen, Carsten Palnæs; Andreassen, Mikkel; Knigge, Ulrich.
Afiliación
  • Holmager P; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Holmager@dadlnet.dk.
  • Langer SW; Department of Endocrinology and Metabolism, Copenhagen University Hospital - Rigshospitalet, Ole Maaløes Vej 24, 2200, Copenhagen, Denmark. Holmager@dadlnet.dk.
  • Kjaer A; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Ringholm L; Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Garbyal RS; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Hansen CP; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Andreassen M; Department of Clinical Physiology, Nuclear Medicine and PET & Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Knigge U; ENETS Neuroendocrine Tumor Centre of Excellence, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Curr Oncol Rep ; 26(2): 114-120, 2024 02.
Article en En | MEDLINE | ID: mdl-38168835
ABSTRACT
PURPOSE OF REVIEW To summarize the literature from the last 5 years on treatment of appendiceal neuroendocrine neoplasms (aNEN). Furthermore, to evaluate the prognostic significance of lymph node metastases, indications for adjuvant treatment, and challenges of the current follow-up regimen. RECENT

FINDINGS:

Simple appendectomy is sufficient in tumors < 1 cm while extended surgery is indicated in tumors > 2 cm. In a multicenter study of aNENs measuring 1-2 cm, extended surgery offered no significant prognostic advantage and is now limited to incomplete tumor resection or high-grade G2 or G3 aNEN. Follow-up remains debatable, as the use of imaging and biomarkers lacks validation. While surgical procedure is well established in aNEN tumors < 1 cm and > 2 cm, the need for extended surgery in aNEN tumors 1-2 cm is questionable. Future studies should address the prognostic impact of lymph node metastases and the optimal design and duration of follow-up.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Apéndice / Tumores Neuroendocrinos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Curr Oncol Rep Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias del Apéndice / Tumores Neuroendocrinos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Curr Oncol Rep Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca